Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (GB:0HTB)
LSE:0HTB
0HTB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Capricor Therapeutics News
Bulls Say, Bears Say
Bulls Say
FDA Approval And Milestone PaymentsDeramiocel’s favorable profile could lead to FDA approval by August 31, 2025, and a concomitant $230M non-dilutive cash infusion.
Strategic PartnershipsCapricor has inked a strategic deal with NS Pharma for U.S. deramiocel commercialization, which includes substantial financial terms and royalties.
Bears Say
Investor ConcernsUpon announcement of the AdCom, CAPR shares sold off significantly, likely from investor concerns with ongoing changes within the FDA.
Regulatory RisksRisks include regulatory, commercial, and payor setbacks for deramiocel.
Options Prices
Currently, No data available
---
Ownership Overview
16.81% Insiders
6.98%
Mutual Funds
0.20% Other Institutional Investors
65.35% Public Companies and Individual Investors
0HTB FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Capricor Therapeutics’s market cap?
Currently, no data Available
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 71 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on May 13, 2025. The company reported -€0.472 earnings per share for the quarter, missing the consensus estimate of -€0.282 by -€0.19.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Capricor Therapeutics have?
Currently, no data Available
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -€0.472 in its last earnings report, missing expectations of -€0.282. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in GB:0HTB
Capricor Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.36 (― Downside)
$36.36 (― Downside)
Blogger Sentiment
Bullish
GB:0HTB Sentiment 75%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
68.86%
12-Months-Change
Fundamentals
Return on Equity
-75.39%
Trailing 12-Months
Asset Growth
210.99%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
0HTB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted positive advancements in the approval process for deramiocel, strong safety and efficacy data, strategic partnerships, and a solid financial position. However, the decline in revenue, increased expenses, and significant net loss cast some concerns on the financial performance. Despite these financial challenges, the strategic and clinical advancements suggest a cautiously optimistic outlook.Read More>0HTB Stock 12 Month Forecast
Average Price Target
€36.36
Akebia Therapeutics
―
Theravance Biopharma
―
Mind Medicine
―
Keros Therapeutics
―
Tyra Bioscience
―